跳到內容

血液科

臨床療效

Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. (開啟新視窗)

Kantarjian HM, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Carpenter N, Mehta B, Franklin J, Giagounidis A

出處‎: Lancet Haematol 2018;5(3):e117-e126.

檢索‎: PubMed 29396092

DOI碼‎: 10.1016/S2352-3026(18)30016-4

https://www.ncbi.nlm.nih.gov/pubmed/29396092 (開啟新視窗)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (開啟新視窗)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

出處‎: Cancer 2013;119(1):107-14.

檢索‎: PubMed 22744794

DOI碼‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (開啟新視窗)